Advertisement

InflammoPharmacology

, Volume 4, Issue 1, pp 91–100 | Cite as

An overview of the key role of misoprostol in the prophylaxis of NSAID-associated ulcers and their complications

  • G. C. Fenn
IVth International Meeting on Side-Effects of Anti-Inflammatory Drugs 7–9 August 1995, Sheffield, UK

Abstract

In 22 controlled endoscopic studies misoprostol has consistently been shown to prevent NSAID-associated gastric and duodenal ulcers. The clinical relevance of such studies has now been proven by the MUCOSA study. This study in 8843 arthritic patients has shown that misoprostol significantly reduces serious NSAID-induced upper GI complications by about half, compared with placebo.

No other therapeutic agent has been shown to reduce serious complications of NSAIDs. In the majority of endoscopic studies H2-receptor blockers and omeprazole prevent duodenal but not gastric ulcers caused by NSAIDs.

Since the serious GI complications caused by NSAIDs arise from the stomach and duodenum in equal proportions, and since we cannot predict the site of occurrence, it is essential that any prophylactic agent should prevent ulcers at both sites. Misoprostol is the only agent consistently shown to do this, and allied with data showing that it reduces GI complications it can play a key role in modifying the natural history of this iatrogenic disease.

Keywords

misoprostol NSAIDs prophylaxis ulcers 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hawkey CJ. NSAIDs and peptic ulcers. Br Med J. 1990;300:278–84.Google Scholar
  2. 2.
    Allison MC, Howatson AG, Torrance CJ, et al. Gastrointestinal damage associated with the use of NSAIDs. N Engl J Med. 1992;327:749–54.PubMedCrossRefGoogle Scholar
  3. 3.
    Soll AM, Kurata J, McGuigan JE. NSAIDs and peptic ulcer disease. Ann Intern Med. 1991;114: 307–19.PubMedGoogle Scholar
  4. 4.
    Blower AL, Brooks A, Fenn GC, et al. Emergency admissions and deaths from UGI crises in relation to NSAID use. Gut. 1994;35(2):S45.Google Scholar
  5. 5.
    Committee on Safety of Medicines. Relative safety of oral non-aspirin NSAIDs. Curr Prob Pharmacogiv. 1994;20:9–11.Google Scholar
  6. 6.
    Rodriguez LAG, Jick H. Risk of UGI bleeding and perforation associated with individual NSAIDs. Lancet. 1994;343:769–72.CrossRefGoogle Scholar
  7. 7.
    Langman MJS, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual NSAIDs. Lancet. 1994;343:1075–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Fenn GC. Controversies in NSAID-induced gastroduodenal damage. Aliment Pharmacol Ther. 1994;8:15–26.PubMedCrossRefGoogle Scholar
  9. 9.
    MacDonald TM, Morant SV, Robinson GC, et al. Risk of UGI complications is constant with continuous NSAID use: a record linkage study. Gut. 1995;36(1):A59.Google Scholar
  10. 10.
    NIH Consensus Panel. Helicobacter pylori in peptic ulcer disease. J Am Med Assoc. 1994;272:65–9.CrossRefGoogle Scholar
  11. 11.
    Graham D. Treatment of peptic ulcers. Editorial. N Engl J Med. 1993;328:349–50.PubMedCrossRefGoogle Scholar
  12. 12.
    Fenn GC. NSAID induced peptic ulceration. Br J Rheumatol. 1993;32:257.PubMedCrossRefGoogle Scholar
  13. 13.
    Shah K, Price, AB, Talbot IC, et al.. Effect of long-term misoprostol coadministration with NSAIDs: a histological study. Gut. 1995;37:195–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Al-Assi MT, Genta RM, Kartunnen TJ, et al. UGI bleeding and GU location are independent clues to NSAID use in patients with peptic ulcer regardless of H. pylori status. Gut. 1995;37:A89.Google Scholar
  15. 15.
    Aadland E, Fausa O, Vata M, et al. Protection by misoprostol against naproxen-induced gastric mucosal damage. Am J Med. 1987;83(1A):37–40.PubMedCrossRefGoogle Scholar
  16. 16.
    Silverstein FE, Kimmey M, Saunders D, et al. Gastric protection by misoprostol against 1300 mg of aspirin. An endoscopic dose-response study. Am J Med. 1987;83(1A):32–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Lanza FL. A double blind study of prophylactic effect of misoprostol on lesions of gastric and duodenal mucosa induced by oral administration of tolmetin in healthy subjects. Br J Clin Pract. 1987; Suppl. 95–101.Google Scholar
  18. 18.
    Lanza FL, Aspinall RL, Swabb EA, et al. Double-blind, placebo-controlled endoscopic comparison of the mucosal protective effects of misoprostol versus cimetidine on tolmetin-induced mucosal injury to the stomach and duodenum. Gastroenterology. 1988;95:289–94.PubMedGoogle Scholar
  19. 19.
    Lanza FL, Peace K, gustitus L, et al. A blinded endoscopic comparative study of misoprostol versus sucralfate and placebo in the prevention of aspirin-induced gastric and duodenal ulceration. Am J Gastroenterol. 1988;83(2):143–6.PubMedGoogle Scholar
  20. 20.
    Jiranek GC, Kimmey MB, Saunders DR, et al. Misoprostol reduces gastroduodenal injury from one week of aspirin: an endoscopic study. Gastroenterology. 1989;96:656–61.PubMedGoogle Scholar
  21. 21.
    Lanza FL, Fakhoui D, Rubin A, et al. A double-blind placebo-controlled comparison of the efficacy and safety of 50, 100 and 200 μg of misoprostol QID in the prevention of ibuprofen-induced gastric and duodenal mucosal lesions and symptoms. Am J Gastroenterol. 1989;84(6):633–6.PubMedGoogle Scholar
  22. 22.
    Lanza FL, Kochman RL, Geis GS, et al. A double-blind placebo-controlled, 6-day evaluation of two doses of misoprostol in gastroduodenal mucosal protection against damage from aspirin and effect on bowel habits. Am J Gastroenterol. 1991;86(12):1743–8.PubMedGoogle Scholar
  23. 23.
    Graham DY, Agrawal NM, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet. 1988;2:1277–880.PubMedCrossRefGoogle Scholar
  24. 24.
    Saggioro A, Alvisi V, Blasi A, et al. Misoprostol prevents NSAID-induced gastroduodenal lesions in patients with OA and RA. Ital J Gastroenterol. 1991;23:119–23.PubMedGoogle Scholar
  25. 25.
    Schimke K, Bolten W. Misoprostol [M] prevents NSAID-induced GI symptoms and lesions: a double-blind placebo [P] controlled study in patients with osteoarthritis. Clin Exp Rheumatol. 1990;8(S4):59.Google Scholar
  26. 26.
    De Rossi A, Brodenfelt R, Bolten W. Prevention of NSAID-induced GI symptoms and lesions by a low daily dosage of misoprostol. Clin Exp Rheumatol. 1980;8(S4):59.Google Scholar
  27. 27.
    Delmas PD, Lambert R, Capron MH. Misoprostol for preventing gastric erosions induced by nonsteroidal antiinflammatory drugs in patients with rheumatic diseases. Rev Rheum (English edition). 1994;61(2):115–20.Google Scholar
  28. 28.
    Elliott SL, Yeomans R, Buchanan R, et al. Efficacy of 12 months’ misoprostol as prophylaxis against NSAID-induced gastric ulcers: A placebo-controlled trial. Scand J Rheumatol. 1994;23(4):171–6.PubMedGoogle Scholar
  29. 29.
    Agrawal NM, Van Kerckhove E, Erhardt L, Geis GS. Prevention of diclofenac-induced gastroduodenal mucosal damage by Cytotec. Dig Dis Sci. 1995;40:1125–31.PubMedCrossRefGoogle Scholar
  30. 30.
    Raskin J, White R, Jaszewski R. Double blind comparative study of the efficacy and safety of misoprostol and ranitidine in the prevention of NSAID-induced gastric ulcers and upper GI symptoms: preliminary findings. Digestion. 1991;49(Suppl.1):50–1.Google Scholar
  31. 31.
    Agrawal NM, Roth S, Graham DY, et al. Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer: a randomized, controlled trial. Ann Intern Med. 1991;115:195–200.PubMedGoogle Scholar
  32. 32.
    Bardhan KD, Griffin W, Fenn GC, et al. The prevention and healing of acute non-steroidal antiinflammatory drug-associated gastroduodenal mucosal damage by misoprostol. Br J Rheumatol. 1993;32:990–5.PubMedCrossRefGoogle Scholar
  33. 33.
    Graham DY, White RM, Moreland L, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann Intern Med. 1993;119(4):257–62.PubMedGoogle Scholar
  34. 34.
    Raskin JB, White R, Sue SO. Efficacy and safety of misoprostol in the prevention of NSAID-induced gastric ulcers—preliminary findings. Gastroenterology. 1993; 104:Abstract 177.Google Scholar
  35. 35.
    Valentini M, Carrizatto R, Poletti M, et al.. Misoprostol (M) vs ranitidine (R) in prevention of NSAID gastroduodenal mucosal injury in cancer patients. J Clin Oncol. 1995;13:2637–42.PubMedGoogle Scholar
  36. 36.
    Bianchi Porro GB, Imbesi B, Montrone F, et al. Double blind dummy comparison of two dosages of misoprostol and ranitidine in the prevention of naproxen induced gastroduodenal mucosal injury. Gastroenterology. 1995;108(4):A60Google Scholar
  37. 37.
    Berkowitz JM, Adler SN, Sharp JT, et al. Reduction of aspirin-induced gastroduodenal mucosal damage with ranitidine. J Clin Gastroenterol. 1986;8(3):377–80.PubMedCrossRefGoogle Scholar
  38. 38.
    Oddsson E, Gudjonsson H, Thjodleifsson B. Comparison between ranitidine and omeprazole for protection against gastroduodenal damage caused by naproxen. Scand J Gastroenterol. 1992;27: 1045–8.PubMedGoogle Scholar
  39. 39.
    Muller P, Simon B. Protective effect of ranitidine versus piroxicam in the stomach and duodenum. An endoscopically controlled double-blind study. Arzneimittelforschung/Drug Res. 1992;42 (II) 12:1492–4.Google Scholar
  40. 40.
    Bianchi Porro G, Pace F, Caruso I. Why are non-steroidal anti-inflammatory drugs important in peptic ulceration? Alim Pharmacol Ther. 1987;1:540A-7S.CrossRefGoogle Scholar
  41. 41.
    Ehsanullah RSB, Page MC, Tildesley G, et al. Prevention of gastroduodenal damage induced by nonsteroidal anti-inflammatory drugs: controlled trial of ranitidine. Br Med J. 1988;297:1017–21.CrossRefGoogle Scholar
  42. 42.
    Robinson MG, Griffen JW, Bowers J, et al. Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal antiinflammatory drugs. Dig Dis Sci. 1989;34:424–8.PubMedCrossRefGoogle Scholar
  43. 43.
    Stalnikowicz R, Goldin E, Fich A, et al. Indomethacin-induced gastroduodenal damage is not affected by cotreatment with ranitidine. J Clin Gastroenterol. 1989;11(2):178–82.PubMedCrossRefGoogle Scholar
  44. 44.
    Yanagawa A. Prophylactic efficacy of ranitidine against gastroduodenal damage from NSAIDs. In: Abstracts of the World Congress of Gastroenterology, Sydney. Abingdon: The Medicine Group UK Ltd. 1990:996.Google Scholar
  45. 45.
    Yanagawa A, Endo T, Nakagawa T, et al. Prophylactic efficacy of the H2 blocker ranitidine against gastroduodenal lesions caused by non-steroidal anti-inflammatory drugs (NSAIDs): controlled trial study. Jpn J Rheumatol. 1991;3(4):275–87.Google Scholar
  46. 46.
    Shaikh S, Mills JG, Darekar B, et al. Ranitidine (150 mg bd) is effective in preventing peptic ulceration in arthritic patients receiving diclofenac (150 mg/day). Gut. 1993;34(1):W52.Google Scholar
  47. 47.
    French P, Darekar BS, Mills JG, et al. Ranitidine in the prevention of NSAID-associated gastric and duodenal ulceration (meta-analysis). Eur J Gastro Hepatol. 1994;6:1141–7.CrossRefGoogle Scholar
  48. 48.
    Hogan DL, Thomas FJ, Isenberg JI. A single dose of cimetidine prevents aspirin-induced gastric damage in man. {jtDig Dis Sci}. {dy1986};{vn31}({sn10}):481S {cm(abstract 1915)}.Google Scholar
  49. 49.
    Stiel D, Ellard K, Hills L, et al. Protective effect of enprostil against aspirin-induced gastroduodenal mucosal injury in man. Am J Med. 1986;81(Suppl. 2A):54–8.PubMedCrossRefGoogle Scholar
  50. 50.
    Kimmey MB, Silverstein F. Role of H2 receptor blockers in the prevention of gastric injury resulting from nonsteroidal anti-inflammatory agents. Am J Med. 1988;84 (Suppl. 2A):49–52.PubMedCrossRefGoogle Scholar
  51. 51.
    Lanza F, Smith L, Davis K, et al. A double blind placebo controlled comparison of two doses of cimetidine and sucralfate in preventing gastroduodenal damage induced by naproxen. Am J Gastroenterol. 1988;83:1034(abstract 68).Google Scholar
  52. 52.
    Aabakken L, Larsen S, Osnes M. Cimetidine tablets or suspension for the prevention of gastrointestinal mucosal lesions caused by non-steroidal anti-inflammatory drugs. Scand J Rheumatol. 1989;18:369–75.PubMedGoogle Scholar
  53. 53.
    Lanza F, Smith L, Davis R, et al. Endoscopic comparison of cimetidine and sucralfate for prevention of naproxen-induced acute gastroduodenal injury. Effect of scoring method. Dig Dis Sci. 1990;35(12): 1494–9.Google Scholar
  54. 54.
    Roth SH, Bennett RE, Mitchell CS, et al. Cimetidine therapy in nonsteroidal anti-inflammatory drug gastropathy. Arch Intern Med. 1987;147:1798–801.PubMedCrossRefGoogle Scholar
  55. 55.
    Stalnikowicz R, Pollack D, Eliakim A, et al. Cimetidine decreases indomethacin induced duodenal mucosal damage in patients with acute musculoskeletal disorders. Gut. 1988;29:1578–82.PubMedCrossRefGoogle Scholar
  56. 56.
    Wallin BA, Grier CE, Fox MJ, et al. Prevention of NSAID-induced ulcers with cimetidine: results of a double-blind, placebo controlled trial. Gastroenterology. 1990;95(5:2):A146.Google Scholar
  57. 57.
    Hunt RH. A clinician’s view of strategies for preventing NSAID-induced gastro-intestinal ulcers. Fourth International Meeting on Side Effects of Anti-Inflammatory Drugs, Sheffield, August 1995, Abstract 9.Google Scholar
  58. 58.
    Aabakken L, Bjornbeth BA, Weberg R, Viksmoen L, Larsen S, Osnes M. NSAID-associated gastroduodenal damage: does famotidine protection extend into the mid- and distal duodenum? Alim Pharmacol Ther. 1990;4:295–303.CrossRefGoogle Scholar
  59. 59.
    Taha AS, Hudson N, Trye P, et al. Prevention of NSAID-related gastric and duodenal ulcers by famotidine. A placebo-controlled double-blind study. Br J Rheumatol. 1994;33(Suppl.2):24.Google Scholar
  60. 60.
    Hudson N, Taha AS, Russell RI, et al. High dose famotidine for healing and subsequent maintenance in non-steroidal anti-inflammatory drug-associated gastroduodenal ulceration. Gut. 1995;36(Suppl. 1): A59.Google Scholar
  61. 61.
    Simon TJ, Berger ML, Hoover ME, Stauffer LA, Bertin RG. A dose-ranging study of famotidine in prevention of gastroduodenal lesions associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Results of a U.S. multicenter trial. Am J Gastroenterol. 1994;89:1644.Google Scholar
  62. 62.
    Muller P, Damman HG, Simon B, et al. Aspirin-induced gastric mucosal damage in man: endoscopic evaluation of the effects of prostaglandin analogues, omeprazole and ranitidine. Gastroenterol Clin Biol. 1985;9:123.Google Scholar
  63. 63.
    Bigard MA. Effet protecteur de l’omeprazole sur les lesions gastriques induites par une prise unique d’aspirine chez l’homme. Gastroenterol Clin Biol. 1988;12:770–1.PubMedGoogle Scholar
  64. 63.
    Oddsson E, Gudjonsson H, Thjodleifsson B. Comparison between ranitidine and omeprazole for protection against gastroduodenal damage caused by naproxen. Scand J Gastroenterol. 1992;27:1045–8.PubMedGoogle Scholar
  65. 64.
    Daneshmend TK et al. Abolition by omeprazole of aspirin induced gastric mucosal injury to man. Gut. 1990;31:514–17.PubMedCrossRefGoogle Scholar
  66. 66.
    Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving NSAIDs. Ann Intern Med. 1995;123:241–9.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • G. C. Fenn
    • 1
  1. 1.SearleHigh WycombeUK

Personalised recommendations